



**Reporting of Transfers of Value to HCPs and HCOs
Methodological Note for Reporting 2024 Data (Reporting Period 01/01/2024 – 31/12/2024) in
2025**

Contents

1. Introduction	4
Approach to disclosure at Alexion	4
2. Definitions	5
2.1. Recipients	5
2.1.1. Definition of an HCP.....	5
2.1.2. Definition of an HCO	5
2.1.3. Definition of a PCO.....	5
2.1.4. Definition of a PO.....	6
2.2. Kind of ToVs	6
2.2.1. Donations.....	6
2.2.2. Sponsorship.....	6
2.2.3. Registration Fees.....	7
2.2.4. Travel and Accommodation.....	7
2.2.5. Fees for Service and Consultancy and Related Expenses	7
2.2.6. Research and Development.....	8
3. Scope of disclosure	8
3.1. Products concerned	8
3.2. Excluded ToVs	8
3.2.1. Hospitality costs	8
3.2.2. Informational and educational materials and items of medical utility	9
3.2.3. Logistical costs	9
3.2.4. Donations to charitable organisations & patient organisations.....	9
3.3. Date of ToVs	9
3.4. Direct ToVs	9
3.5. Indirect ToVs	10
3.5.1. Indirect ToVs through third parties for R&D Activities.....	10
3.5.2. Indirect ToVs through PCOs.....	10
3.5.3. Indirect ToVs through HCOs.....	10
3.5.4. Indirect ToVs through other third parties.....	10
3.6. ToVs in case of partial attendances or cancellation	10
3.7. Cross-border activities	11

3.7.1. Cross-border activities	11
4. Specific considerations.....	11
4.1. Country unique identifier	11
4.2. Self-incorporated HCP	11
5. Consent management	11
5.1. Consent collection	Error! Bookmark not defined.
6. Disclosure form	11
6.1. Disclosure platform	11
6.1.1. Date of publication	11
6.1.2. Retention of data	12
6.2. Disclosure language.....	12
7. Disclosure financial data	12
7.1. Currency.....	12
7.2. Value added tax (VAT) and other taxes.....	12

1. Introduction

Approach to disclosure at Alexion

Collaborative working between medical professionals and healthcare organisations has long been a positive driver for advancements in patient care and the development of innovative medicine. Medical professionals and the organisations with whom they work provide the pharmaceutical industry with valuable, independent and expert knowledge derived from their clinical and disease management experience. Furthermore, as the primary point of contact with patients, the medical professional can offer invaluable expert knowledge on patient outcomes and therapy management. This helps to adapt our products to better suit patients and thereby improve patient care overall.

Healthcare professionals and organisations should be fairly compensated for the services they provide to pharmaceutical companies. The EFPIA Code of Practice provides accuracy and transparency in disclosing the scope and value of such collaborative work, and it will become an important step towards building greater trust between the pharmaceutical industry, medical community and patients.

Alexion is a subsidiary of AstraZeneca a member company of science industries (Pharma Cooperation Code signatory) and a full corporate member of EFPIA. As such Alexion is committed to transparency around interactions with Healthcare Professionals (HCPs), Healthcare Organisations (HCOs), and Patient Organisations (POs) and that these are captured and reported in line with all applicable local transparency requirements.

Alexion's policies are fully aligned with the aims of the EFPIA Code of Practice and its local interpretation in the "Code of Practice for the Pharmaceutical Industry" – to promote ethical and transparent interactions with the Healthcare community. Our interactions with HCPs/HCOs/POs are governed by the ALEXION Code of Ethics and supporting Global Standards which require that we run every part of our business with integrity and refuse to give or receive anything of value that may be extended or could be seen as improper influence.

Producing transparency reporting is an opportunity for Alexion to demonstrate its commitment to the values and principles behind the EFPIA Code of Practice and other transparency requirements in Europe.

The objective of this note is to explain Alexion's approach to disclosure, to include key definitions, the scope of disclosed activities and key elements of the process followed to capture and report data.

At a high level, there are three main tenets that characterize the Alexion approach:

(1) Affiliate accountability and regional consolidation

Affiliates are responsible for capturing the Transfers of Value (ToVs) made in their affiliates and for validating the accuracy of the data. A regional reporting solution consolidates the ToVs, providing consistency and automating inclusion of cross border payments within Europe. Other cross border payments are collected through a payment system (US) or manually (rest of world).

(2) Compliance with local codes

Unless there are strong legal mandatory requirements, affiliates have transposed the Code in full, that is, without deviations. In each country, Alexion will comply with applicable local disclosure requirements. There may be variations (stricter than the provision in the Code) or deviations (where because of mandatory national regulations the code cannot be transposed in full).

(3) One disclosure per market, including all ToVs paid directly through entities belonging to Alexion or indirectly through third parties acting on behalf of Alexion

The entity included in reporting for Switzerland is: Alexion Pharma GmbH.

For Switzerland, disclosure is made through Alexion's external website under the Transparency section at <https://alexion.com/our-company/ethical-standards>.

2. Definitions

2.1. Recipients

2.1.1. Definition of an HCP

The definition of an HCP in Switzerland is:

Healthcare professionals: physicians, dentists and pharmacists who are working in particular in a practice or hospital together with pharmacists and druggists active in retail businesses and persons who are authorised by Swiss law on therapeutic products to prescribe, deliver or use medicinal products for humans.

2.1.2. Definition of an HCO

The definition of an HCO in Switzerland is:

Healthcare organisations: institutions, organisations, associations or other groups of healthcare professionals which provide healthcare services or consultancy or other services in healthcare (for example hospitals, clinics, foundations, universities or other educational establishments, scientific societies or professional associations, community practices or networks, but not patient organisations).

2.1.3. Definition of a PCO

The definition of a PCO in Switzerland is:

A PCO is a company/individual specialised in the organisation and management of congresses, conferences, seminars and similar events (all "Events"). For the application of this Guidance, commercial companies involved in organisation of travel (travel agencies) or accommodation (hotels, banqueting functions in hotels, etc.) are not considered PCOs.

2.1.4. Definition of a PO

The definition of PO in Switzerland is:

A non-for-profit legal person/entity (including the umbrella organisation to which it belongs), mainly composed of patients and/or caregivers, that represents and/or supports the needs of patients and/or caregivers and which business address, place of incorporation or primary place of operation is in Europe.

2.2. Kind of ToVs

2.2.1. Donations

Alexion provides support without expecting any service in return for medical or scientific education, advances in medical or scientific research, health or healthcare systems or disaster relief through financial or non-financial ToVs to legitimate, established organisations.

Alexion can provide this support through:

- Donations to support initiatives in HCP Education, including education about healthcare systems and practices, Medical or Scientific Research, or Partnerships.
- Donations to a non-profit or public sector healthcare organisation (HCO) or Patient Organisations (PO) intended to support their charitable mission and activities.

Donations to HCOs can be both monetary and donations in kind. Product Donations are given in circumstances of national emergency, international or national disaster relief or other genuine public health need. Alexion charitable product donations and processes are aligned to the World Health Organisation (WHO) Guidelines for Drug Donations.

2.2.2. Sponsorship

Alexion gives contributions, through financial or non-financial support to legitimate, established organisations for medical or scientific education of external stakeholders, organizing or hosting educational or scientific events (including independent congresses) and Alexion gets back a defined service in return. These contributions aim to increase the scientific or educational quality of the event and/or support with logistics in modest venues or with incidental hospitality, in line with Alexion's own ethical principles. The mandatory Sponsorship Agreements will describe the purpose of the sponsorship and for what the funds are to be used.

Sponsorship packages may also include satellite symposia and the sponsoring of speakers or faculty.

ToVs are made to either the HCO directly or to an event organizer or other third party appointed by the HCO to manage the event. In all cases, ToVs are disclosed against the HCO that ultimately benefits.

Where contributions made to HCOs include support for travel & accommodation for HCPs to attend Independent Congresses and the HCPs benefitting from this support are unknown, this payment will be assigned to the EFPIA category "Sponsorship Agreements".

2.2.3. Registration Fees

As part of support to continuous medical education, Alexion provides support to HCOs or HCPs to cover the costs of registration fees for HCPs to attend selected independent congresses and where provided to HCOs, also for other educational/scientific events.

Where these are provided to HCOs, Alexion is not involved in the selection of the HCPs.

Where these are provided to individual HCPs, the purpose of the support is to enable delegates:

- to attend presentations or participate in scientific exchange on significant developments related to Alexion products or uses or related to Alexion's scientific research; or,
- to support the performance of a contract for services.

All arrangements are generally paid directly to travel and or /accommodation providers or organiser.

2.2.4. Travel and Accommodation

As part of support to continuous medical education, Alexion provides support to HCOs or HCPs to cover the costs for Travel and Accommodation for HCPs to attend selected independent congresses and/or Alexion Organised Meetings and where provided to HCOs for other educational/scientific events.

These costs can include costs of flights, trains, hotel accommodation, taxis, bus transfers, and other travel costs.

Costs for ground transportation (for example bus or taxi) that are organised for group transportation and not assigned to certain HCPs are reported in aggregate, but where the identity of the HCPs is known, these are split by HCP.

2.2.5. Fees for Service and Consultancy and Related Expenses

Alexion engages an HCP/HCO/PO for services when there is a genuine and legitimate business need and where the HCP/HCO/PO is qualified and appropriate to provide the services. These services are paid with a Fee for Service at Fair Market Value.

These services can include:

- Speaking at and chairing meetings
- Training services
- Participation at advisory board meetings
- Medical writing
- Data analysis
- Development of education materials
- General consulting/advising
- Services performed in connection with a third party congress
- Retrospective Non-interventional studies

- Participation in market research where such participation involves remuneration and/or travel. Payments for these services are only disclosed if Alexion is aware of the identity of those participating in the market research.

As part of the written Fee for Services Agreement, related expenses can be paid for and can include costs of flights, trains, car hire, tolls, parking fees, taxis, bus transfers, hotel accommodation and any visa costs. All costs are paid by Alexion to travel and or /accommodation providers or meeting organizers (where relevant) or reimbursed supported by appropriate receipts.

2.2.6. Research and Development

All ToVs related to the planning or conduct of non-clinical studies, clinical trials and non-interventional studies performed by Alexion or by Clinical Research Organisations on Alexion's behalf that are prospective in nature are considered Research & Development ToVs and are reported on an aggregate basis.

Externally Sponsored Scientific Research is conducted and managed by a non-Company researcher who assumes the legal and/or regulatory accountability for the research as defined by applicable regulations and laws of the country involved. Financial support for approved programs falls under the category of R&D activities and is reported on an aggregate basis.

Retrospective non-interventional studies or other studies that are not submitted to authorities as per local drug law do not fall under the category of R&D activities. The ToVs related to those studies will be reported as Fee for Service under name of the individual recipient.

3. Scope of disclosure

3.1. Products concerned

Alexion is a science-focused company, developing innovative medicines that are prescription only medicines and interactions with HCPs/HCOs/POs are focused on the development and promotion of prescription medicines. Consequently, only ToVs relating to prescription medicines are being disclosed.

3.2. Excluded ToVs

3.2.1. Hospitality costs

As per Art 10 of the EFPIA Code of Practice, hospitality costs are not disclosable if in line with the limits set within the national association. Alexion applies these limits for Alexion Organised & Sponsored Meetings, and therefore costs of meals & drinks are excluded. However, where meals and drinks make up an integral and inseparable part of contributions to the cost of events or sponsoring as part of Sponsorship Agreements with HCOs, they have been included in Contributions to Cost of Events.

3.2.2. Informational and educational materials and items of medical utility

As per Art 17 EFPIA Code of Practice, items of medical utility for HCPs and informational and educational material are not disclosed where "The transmission of informational or educational materials is permitted provided it is: (i) "inexpensive"; (ii) directly relevant to the practice of medicine or pharmacy; and (iii) directly beneficial to the care of patients."

3.2.3. Logistical costs

Logistical costs related to Alexion Organised Meetings (for example room hire, technics, personnel) are excluded. However, ToVs to participants, such as support for travel and accommodation or speaker fees to HCPs are included in the relevant cost category.

3.2.4. Donations to charitable organisations & patient organisations

All ToVs to non-HCO organisations are out of scope and excluded for example charitable organisations.

All ToVs to Patient Organisations are in scope for reporting as outlined in the EFPIA Code of Practice on Relationships between the Pharmaceutical Industry and patient organisations.

3.3. Date of ToVs

Where the ToV is a payment, values are reported on the date of the payment. Payments made in 2024 for activities related to 2023 are included. If consent to disclose these has been obtained, they are reported against the individual. If not, they will be reported in aggregate.

Where ToVs relate to multi-year contracts, only the ToVs made in the reporting year are included.

Where the ToV is a benefit in kind, values are reported on the date the recipient received the benefit.

3.4. Direct ToVs

The natural or legal person that holds the bank account on which the money is transferred is considered the recipient of the ToV and will be disclosed.

Direct ToVs are captured in SAP and flow into Alexion transparency reporting system based on their vendor code, General Ledger code and activity code. They are then mapped to the appropriate EFPIA disclosure activity category for reporting. In the case of direct ToV transactions that are made outside of the EFPIA member countries, these are uploaded to the transparency system via a manual template (based on actual payment data in another SAP system).

3.5. Indirect ToVs

3.5.1. Indirect ToVs through third parties for R&D Activities

Where a third-party providing services for R&D activities acts on behalf of Alexion to make ToVs to HCPs/HCOs, these are within scope and are reported at an aggregate level under R&D (as long as their activities fall within the scope of the definition of R&D activities).

3.5.2. Indirect ToVs through PCOs

Contributions provided to Events through PCOs, that would therefore be the Recipient of the ToVs, must be considered as indirect ToVs. ToVs through PCOs are reported either in the name of benefitting HCO, or in the name of Recipient PCO if the HCO is unknown. This applies whether PCOs organise Events on their own initiative, or at the request of an HCO.

Contribution to costs related to Events paid through PCOs to the benefit of individual HCPs must be reported on an individually named basis, as Indirect ToVs to HCPs, or in the name of Recipient PCO if the HCP is unknown. Disclosures on an individual names basis are subject to appropriate consent; where such consent cannot be secured, related ToVs will be disclosed in aggregate.

3.5.3. Indirect ToVs through HCOs

Where ToVs are made to an individual HCP indirectly via an HCO and where Alexion has obtained the consent, these will be disclosed against the HCO in line with local association guidelines.

3.5.4. Indirect ToVs through other third parties

Where third parties are appointed by an HCO to manage an event, and where the HCO ultimately benefits from that ToV, these ToVs are disclosed against the HCO. Where an event is organised on behalf of multiple HCOs without clarity on allocation, the value is divided equally between the HCOs.

Where third parties are appointed by Alexion to make travel and accommodation arrangements for HCPs who are providing services or are supported to attend events, these ToVs are disclosed against the HCP.

Any additional administration fees charged by agencies are not included, as these are not ToVs to HCPs or HCOs.

3.6. ToVs in case of partial attendances or cancellation

Where an HCP/HCO does not receive the benefit due to a no show or a cancellation of event, the associated costs are not reported, such as the cost of cancelling a hotel booking or accommodation. In case of partial attendance, only the benefits actually received are reported.

Where Alexion has to pay cancellation fees to HCP/HCOs as per service contracts, due to cancellation of initiatives or events, these payments are reported.

3.7. Cross-border activities

3.7.1. Cross-border activities

Alexion makes their best efforts to capture and report all ToVs to HCPs, HCOs, and POs with their primary practice in a country with EFPIA Code of Practice and/or other cross border transparency reporting requirements and has introduced a group wide reporting requirement for that purpose. The country of disclosure will be determined by the address of principal practice for HCPs and the address of registration for an HCO.

Disclosures are made locally, either on each affiliate's website, or on a separate disclosure platform if prescribed by the national code or law.

4. Specific considerations

4.1. Country unique identifier

Alexion provides one unique identifier for any HCP, HCO, or PO that is to be reported. This ID is generated by Alexion and is used to ensure that transactions are reported against the correct recipient to facilitate collection of ToVs throughout Europe and across other affiliates.

4.2. Self-incorporated HCP

Where a self-employed HCP is incorporated in a legal entity that consists of only that one HCP, this is considered as an HCO, as it is a legal entity but remains subject to providing consent, as per data privacy recommendations.

If an HCP is "self-employed" but has not set up a legal entity, they are treated as an individual HCP.

5. Consent management

5.1. Consent collection

Consent was not obtained for data collection year 2024. As such, to comply with data privacy regulations, Alexion will disclose individual HCP and HCO ToVs in their respective aggregate sections of the disclosure report.

6. Disclosure form

6.1. Disclosure platform

6.1.1. Date of publication

The date of publication for Switzerland is latest 30 June in line with Pharma Cooperation Code.

6.1.2. Retention of data

Alexion maintains relevant records of the disclosures for a minimum of 5 years.

6.2. Disclosure language

Disclosure is made in French and German.

7. Disclosure financial data

7.1. Currency

Disclosure will be made in Euro. For in scope transactions requiring conversion, the calculation will be applied when the transaction is moved to the reporting environment, using the AstraZeneca Uniform Reference Environment (AZURE) rates. AZURE is what Alexion utilizes for conversion rates for each currency.

7.2. Value added tax (VAT) and other taxes

VAT is excluded and Withholding Tax (WHT) is included.